within Pharmacolibrary.Drugs.ATC.J;

model J01XX11
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.91,
    Cl             = 0.00010333333333333333,
    adminDuration  = 600,
    adminMass      = 200 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.06720000000000001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0095,
    Tlag           = 10.200000000000001,            
    Vdp             = 0.0171,
    k12             = 7.2,
    k21             = 7.2
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J01XX11</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Tedizolid is an oxazolidinone-class antibacterial agent, primarily used for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). It is approved for use in adults and adolescents.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after administration of tedizolid phosphate 200 mg orally once daily.</p><h4>References</h4><ol><li><p>Tantalo, LC, et al., &amp; Mitjà, O (2023). Antimicrobial susceptibility of Treponema pallidum subspecies pallidum: an in-vitro study. <i>The Lancet. Microbe</i> 4(12) e994–e1004. DOI:<a href=&quot;https://doi.org/10.1016/S2666-5247(23)00219-7&quot;>10.1016/S2666-5247(23)00219-7</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37827185/&quot;>https://pubmed.ncbi.nlm.nih.gov/37827185</a></p></li><li><p>Bradley, JS, et al., &amp; Prokocimer, P (2016). Pharmacokinetics, Safety and Tolerability of Single Oral or Intravenous Administration of 200 mg Tedizolid Phosphate in Adolescents. <i>The Pediatric infectious disease journal</i> 35(6) 628–633. DOI:<a href=&quot;https://doi.org/10.1097/INF.0000000000001096&quot;>10.1097/INF.0000000000001096</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26910588/&quot;>https://pubmed.ncbi.nlm.nih.gov/26910588</a></p></li><li><p>Flanagan, S, et al., &amp; Prokocimer, P (2014). Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment. <i>Antimicrobial agents and chemotherapy</i> 58(11) 6471–6476. DOI:<a href=&quot;https://doi.org/10.1128/AAC.03431-14&quot;>10.1128/AAC.03431-14</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25136024/&quot;>https://pubmed.ncbi.nlm.nih.gov/25136024</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J01XX11;
